- AnaptysBio is a $675M clinical-stage biotechnology company focused on developing immunology therapeutics based around emerging immune control mechanisms applicable to inflammation and immuno-oncology.
- AnaptysBio has 7 clinical-stage therapeutics: 4 wholly-owned including the promising Imsidolimab (Phase 2) and the not-so-promising Etokimab (Phase 2), as well as one GSK-therapeutic expected to get approval in 4Q 2020.
- AnaptysBio is currently sitting on a safe $338M in cash and is expected to get another $60M from the GSK-collaborations' new-amendment and royalty structure leaving risk strictly concerning the science.
- Imsidolimab's End-Of-Phase 2 FDA meeting is expected to take place in Q4 2020 and aims to report full data in 2021.
- In summary, the author projects AnaptysBio as a "buy" at a 1-year price target of $41.28 (+61% upside).
For further details see:
AnaptysBio: Imsidolimab Q4 FDA Meeting, Dostarlimab Q4 2020 Approval, And New Trial Initiations, 61% Upside